Biotechnology company CSL will buy back up to $500 million shares to improve returns and earnings per share.
The announcement comes as chairman John Shine said the company's $1 billion buyback, announced last October, is 91 per cent complete.
That buyback boosted earnings per share by 25 per cent in the period to June, he said.
"Through this ongoing program of buybacks, all CSL shareholders benefit from improved investment return ratios, including earnings per share and return on equity," Professor Shine said in a statement.
